Business
AstraZeneca agrees to buy US FDA Priority Review
AstraZeneca agrees to buy US FDA Priority Review.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 8484J AstraZeneca PLC 22 August 2019 \n\n22 August 2019 07:00 BST \n \nAstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi\n \nAstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). \n \nA PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval.\n \nThe transaction is subject to clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.\n \nFor the purposes of the UK Listing Authority's Listing Rule LR 10.4.1 R (Notification of class 2 transactions), the total book value of gross assets attributable to the PRV is equivalent to the full consideration of $95m. No operating profit or loss was attributable to the PRV in prior accounting periods at Sobi.\n \nAbout AstraZeneca \nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca. \n\n\n\n\n \n \nMedia Relations\n\n\n \n\n\n \n\n\n\n\nGonzalo Viña \n\n\n \n\n\n+44 203 749 5916\n\n\n\n\nRob Skelding\n\n\nOncology\n\n\n+44 203 749 5821\n\n\n\n\nRebecca Einhorn\n\n\nOncology\n\n\n+1 301 518 4122\n\n\n\n\nMatt Kent\n\n\nBioPharmaceuticals\n\n\n+44 203 749 5906\n\n\n\n\nJennifer Hursit\n\n\nOther\n\n\n+44 203 749 5762\n\n\n\n\nChristina Malmberg Hägerstrand\n\n\nSweden\n\n\n+46 8 552 53 106\n\n\n\n\nMichele Meixell\n\n\nUS\n\n\n+1 302 885 2677\n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nInvestor Relations\n\n\n \n\n\n \n\n\n\n\nThomas Kudsk Larsen\n\n\n \n\n\n+44 203 749 5712\n\n\n\n\nHenry Wheeler\n\n\nOncology\n\n\n+44 203 749 5797\n\n\n\n\nChrister Gruvris\n\n\nBioPharmaceuticals (CV, metabolism)\n\n\n+44 203 749 5711\n\n\n\n\nNick Stone\...